Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24460040 | 0.87 | GAA (0.51) | GAAMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL16122760 | 0.87 | KRAS (0.53) | KRASGAAEGFRERBB2MAPT | |
| SCHEMBL16122813 | 0.87 | KRAS (0.53) | KRASGAAEGFRERBB2MAPT | |
| SCHEMBL15337756 | 0.86 | KRAS (0.60) | KRASGAAEGFRERBB2MAPT | |
| SCHEMBL16117760 | 0.84 | KRAS (0.50) | KRASGAAEGFRERBB2KMT2A | |
| SCHEMBL25936101 | 0.83 | KRAS (0.71) | KRASGAAEGFRMAPTTSHR | |
| SCHEMBL16122744 | 0.83 | KRAS (0.49) | KRASGAAEGFRERBB2ALDH1A1 | |
| SCHEMBL25936148 | 0.83 | KRAS (0.55) | KRASGAAMAPTALDH1A1KDM4E | |
| SCHEMBL16122360 | 0.83 | KRAS (0.57) | KRASGAAEGFRERBB2MAPT | |
| SCHEMBL16122614 | 0.82 | KRAS (0.54) | KRASGAAEGFRERBB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | KRAS 1/4885GAA 2090/4885EGFR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.